Related Experiment Video
Updated: Jun 29, 2025
07:54
Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
Published on: December 6, 2016
19.8K
Dimdazenil: First Approval
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|March 28, 2024
Summary
Dimdazenil, a novel partial positive allosteric modulator of the gamma-aminobutyric acid (GABA)A receptor, has been approved in China for insomnia. This development aims to provide a safer alternative to traditional GABAA agonists.
Area of Science:
- Pharmacology
- Neuroscience
- Drug Development
Background:
- Insomnia is a prevalent sleep disorder with significant public health implications.
- Current treatments, primarily full GABAA receptor agonists, are associated with tolerance, withdrawal, and adverse effects.
- There is a need for novel insomnia therapeutics with improved safety profiles.
Purpose of the Study:
- To summarize the development milestones of dimdazenil.
- To highlight the regulatory approval of dimdazenil for insomnia treatment.
Main Methods:
- Review of preclinical and clinical development data for dimdazenil.
- Analysis of regulatory submission and approval process in China.
Main Results:
- Dimdazenil, a small-molecule, oral, partial positive allosteric modulator of GABAA receptors, has been developed.
- On November 29, 2023, dimdazenil oral capsules received approval in China for short-term insomnia treatment.
- The drug is designed to mitigate issues like tolerance and withdrawal linked to full GABAA agonists.
Conclusions:
- Dimdazenil represents a significant advancement in insomnia pharmacotherapy.
- The approval marks a key milestone, offering a potentially safer treatment option for patients with insomnia.
Related Concept Videos
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
171
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
171
01:19Sedatives and Hypnotics Drugs: Benzodiazepines
243
Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
243
01:23Sedatives and Hypnotics: Overview
358
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
358
01:29Anxiolytic Drugs: Benzodiazepines and Buspirone
723
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
723
01:19Management of Insomnia
244
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
244
01:18Drug Delivery: Enteral Route
437
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
437